MA29160B1 - Derives de triazole substitues, servant d'antagonistes d'ocytocine - Google Patents

Derives de triazole substitues, servant d'antagonistes d'ocytocine

Info

Publication number
MA29160B1
MA29160B1 MA30089A MA30089A MA29160B1 MA 29160 B1 MA29160 B1 MA 29160B1 MA 30089 A MA30089 A MA 30089A MA 30089 A MA30089 A MA 30089A MA 29160 B1 MA29160 B1 MA 29160B1
Authority
MA
Morocco
Prior art keywords
ocytocin
antagonists
triazole derivatives
substituted triazole
substituted triazoles
Prior art date
Application number
MA30089A
Other languages
English (en)
Inventor
Alan Daniel Brown
Andrew Antony Calabrese
David Ellis
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA29160B1 publication Critical patent/MA29160B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE DES TRIAZOLES SUBSTITUÉS REPRÉSENTÉS PAR LA FORMULE (I), LES UTILISATIONS DE CES TRIAZOLES SUBSTITUÉS, DES PROCÉDÉS DE PRÉPARATION DE CES TRIAZOLES SUBSTITUÉS, AINSI QUE DES COMPOSITIONS CONTENANT CES COMPOSÉS. CES INHIBITEURS SONT UTILISÉS DANS DIVERS DOMAINES THÉRAPEUTIQUES, NOTAMMENT DANS LA DYSFONCTION SEXUELLE.
MA30089A 2005-01-20 2007-07-20 Derives de triazole substitues, servant d'antagonistes d'ocytocine MA29160B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0501190.3A GB0501190D0 (en) 2005-01-20 2005-01-20 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
MA29160B1 true MA29160B1 (fr) 2008-01-02

Family

ID=34259404

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30089A MA29160B1 (fr) 2005-01-20 2007-07-20 Derives de triazole substitues, servant d'antagonistes d'ocytocine

Country Status (32)

Country Link
US (5) US7557131B2 (fr)
EP (1) EP1841758B1 (fr)
JP (1) JP4124805B1 (fr)
KR (1) KR100936854B1 (fr)
CN (1) CN101107243B (fr)
AP (1) AP2007004047A0 (fr)
AR (1) AR055303A1 (fr)
AT (1) ATE449091T1 (fr)
AU (1) AU2006207300B2 (fr)
BR (1) BRPI0606463A2 (fr)
CA (1) CA2595569C (fr)
CR (1) CR9219A (fr)
DE (1) DE602006010508D1 (fr)
DK (1) DK1841758T3 (fr)
DO (1) DOP2006000014A (fr)
EA (1) EA200701328A1 (fr)
ES (1) ES2334517T3 (fr)
GB (1) GB0501190D0 (fr)
GT (1) GT200600024A (fr)
HK (1) HK1113927A1 (fr)
IL (1) IL184148A (fr)
MA (1) MA29160B1 (fr)
MX (1) MX2007008757A (fr)
NL (1) NL1030961C2 (fr)
NO (1) NO338420B1 (fr)
PA (1) PA8660401A1 (fr)
PE (1) PE20060875A1 (fr)
TN (1) TNSN07275A1 (fr)
TW (1) TW200637847A (fr)
UY (1) UY29339A1 (fr)
WO (1) WO2006077496A1 (fr)
ZA (1) ZA200705718B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06284516A (ja) * 1993-03-31 1994-10-07 Mitsubishi Electric Corp 電気車制御装置
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
WO2006130986A1 (fr) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
WO2007143823A1 (fr) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US7754745B2 (en) * 2006-06-13 2010-07-13 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2008133975A1 (fr) * 2007-04-26 2008-11-06 Avalon Pharmaceuticals Composés polycycliques et leurs utilisations
CN101981006B (zh) 2008-01-31 2013-08-28 赛诺菲-安万特 环状吲哚-3-甲酰胺、其制备和其作为药物的用途
PT2240482E (pt) * 2008-01-31 2013-09-06 Sanofi Sa Azaindole-3-carboxamidas cíclicas, sua preparação e sua utilização como fármacos
US9340511B2 (en) * 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
DK3541784T3 (en) 2016-11-18 2023-10-23 Integrative Res Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
JP2020502211A (ja) 2016-12-21 2020-01-23 江蘇恒瑞医薬股▲ふん▼有限公司 縮合環基を有するアザシクロブチルトリアゾール誘導体、その製造方法および医薬におけるその使用
WO2018121551A1 (fr) 2016-12-28 2018-07-05 江苏恒瑞医药股份有限公司 Dérivé de triazole azabicyclo-substitué, sa méthode de préparation et son application en médecine
WO2019242642A1 (fr) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 Sel pharmaceutiquement acceptable et forme cristalline d'un inhibiteur d'otr et procédé de préparation associé
TW202016092A (zh) * 2018-06-20 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｏｔｒ抑制劑的晶型及其製備方法
WO2020001460A1 (fr) * 2018-06-27 2020-01-02 江苏恒瑞医药股份有限公司 Sel pharmaceutiquement acceptable, forme cristalline d'un dérivé de triazole substitué par azabicyclo et procédé de préparation
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
CN113582818B (zh) * 2021-08-30 2023-08-01 上海日异生物科技有限公司 一种3-卤-2-烷基苯酚的合成方法
WO2023156386A2 (fr) * 2022-02-16 2023-08-24 Duke Street Bio Limited Composé pharmaceutique
CN114805161B (zh) * 2022-06-14 2023-08-25 南通华祥医药科技有限公司 一种3-氟丫丁啶盐酸盐的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US5053411A (en) 1989-04-20 1991-10-01 Anaquest, Inc. N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1997036876A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
CA2250204A1 (fr) 1996-04-03 1997-10-09 Neville J. Anthony Inhibiteurs de la farnesyl-proteine transferase
WO1997036881A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
EP0891356A1 (fr) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
EP1003374A1 (fr) 1996-12-30 2000-05-31 Merck & Co., Inc. Inhibiteurs de farnesyl-proteine transferase
EA200000526A1 (ru) 1997-12-16 2000-12-25 Пфайзер Продактс Инк. Комбинация, эффективная для лечения импотенции
US7008954B1 (en) 1999-07-23 2006-03-07 Shionogi & Co., Ltd. Th2 differentiation inhibitors
NZ517999A (en) 1999-10-15 2004-07-30 F Benzodiazepine derivatives
EP1232147B1 (fr) 1999-11-15 2008-04-02 Janssen Pharmaceutica N.V. Triazoles utilises comme inhibiteurs de farnesyl transferase
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
AU2001256769A1 (en) * 2000-05-19 2001-11-26 Merck Patent Gmbh Triazole derivatives
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
WO2003093242A2 (fr) 2001-10-03 2003-11-13 Pharmacia Corporation Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
BRPI0414663A (pt) * 2003-09-22 2006-11-21 Pfizer derivados triazol substituìdos como antagonistas de oxitocina
OA13347A (en) 2003-12-22 2007-04-13 Pfizer Triazole derivatives as vasopressin antagonists.
WO2005082866A2 (fr) * 2004-02-20 2005-09-09 Pfizer Limited Derives de triazole substitues utilises en tant qu'antagonistes de l'oxytocine
EP1742932A1 (fr) 2004-04-28 2007-01-17 Pfizer Limited Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists

Also Published As

Publication number Publication date
GT200600024A (es) 2006-08-23
GB0501190D0 (en) 2005-03-02
CA2595569C (fr) 2010-07-20
TNSN07275A1 (fr) 2008-12-31
EP1841758A1 (fr) 2007-10-10
EA200701328A1 (ru) 2007-12-28
US9023872B2 (en) 2015-05-05
AU2006207300B2 (en) 2011-03-03
ZA200705718B (en) 2008-08-27
US20170114040A1 (en) 2017-04-27
NO338420B1 (no) 2016-08-15
US8207198B2 (en) 2012-06-26
CN101107243A (zh) 2008-01-16
ATE449091T1 (de) 2009-12-15
BRPI0606463A2 (pt) 2009-06-30
AR055303A1 (es) 2007-08-15
DK1841758T3 (da) 2010-01-18
JP4124805B1 (ja) 2008-07-23
MX2007008757A (es) 2008-03-10
ES2334517T3 (es) 2010-03-11
CA2595569A1 (fr) 2006-07-27
NL1030961A1 (nl) 2006-07-21
JP2008528476A (ja) 2008-07-31
UY29339A1 (es) 2006-08-31
US20090253674A1 (en) 2009-10-08
US20150322042A1 (en) 2015-11-12
KR100936854B1 (ko) 2010-01-14
AU2006207300A1 (en) 2006-07-27
CN101107243B (zh) 2010-11-24
AP2007004047A0 (en) 2007-06-30
CR9219A (es) 2007-07-24
WO2006077496A1 (fr) 2006-07-27
PA8660401A1 (es) 2006-09-08
HK1113927A1 (en) 2008-10-17
US10150752B2 (en) 2018-12-11
IL184148A (en) 2013-06-27
NL1030961C2 (nl) 2007-01-12
IL184148A0 (en) 2007-10-31
DE602006010508D1 (de) 2009-12-31
DOP2006000014A (es) 2006-07-31
TW200637847A (en) 2006-11-01
EP1841758B1 (fr) 2009-11-18
NO20074177L (no) 2007-10-16
US20130137671A1 (en) 2013-05-30
US9394278B2 (en) 2016-07-19
KR20070091023A (ko) 2007-09-06
PE20060875A1 (es) 2006-09-04
US20060160786A1 (en) 2006-07-20
US7557131B2 (en) 2009-07-07

Similar Documents

Publication Publication Date Title
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN07022A1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2009000450A1 (fr) Derives de pyridine
TW200505903A (en) CGRP receptor antagonists
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA31766B1 (fr) Composés organiques
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA30289B1 (fr) Dérivés d'amines
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
SI1778677T1 (sl) Heterociklične kondenzirane spojine uporabne kotprotidiuretični agensi
EP1615914A4 (fr) Antagonistes des recepteurs de cgrp
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
TNSN04225A1 (fr) Derives de benzoxazine en tant que modulateurs de 5-ht6 et utilisations de ceux-ci
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen